{ "items": [ "\n\n
\n \n 14 April 2021\n \n
\n\n \n \n \n\n \n \n \nResearchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
\n \n\n\n \n 7 April 2021\n \n
\n\n \n \n \n\n \n \n \nToday, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.\r\n\r\nBoth the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the EU's European Medicines Agency have concluded that whilst there was a possible link from these very rare blood clots to the vaccine, the benefits of vaccination continue to outweigh the risks in all age groups, and have requested the product information is updated to mitigate further risks.
\n \n\n\n \n 25 March 2021\n \n
\n\n \n \n \n\n \n \n \nOur partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
\n \n\n\n \n 24 March 2021\n \n
\n\n \n \n \n\n \n \n \nThe VALIDATE Network, a community of over 400 researchers based in more than 200 research institutions in 63 countries, will today launch the \u201cBCG100 Programme\u201d marking the centenary of the Bacille Calmette-Gu\u00e9rin Vaccine for tuberculosis. BCG100 officially launches with the \u2018BCG Then and Now\u2019 online lecture by Professor Helen McShane, VALIDATE Network Director and Jenner Investigator and Professor Paul Fine, London School of Hygiene and Tropical Medicine. Taking place at 6pm GMT, 24 March 2021, the talk will cover the initial development of the vaccine, moving through to the modern-day challenges in the fight against TB and the future challenges researchers face in replacing the enduring BCG vaccine.
\n \n\n\n \n 22 March 2021\n \n
\n\n \n \n \n\n \n \n \nA Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
\n \n\n\n \n 18 March 2021\n \n
\n\n \n \n \n\n \n \n \nScientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise \u2013 or stop infection from \u2013 variants that are circulating in South Africa, Brazil and elsewhere. These data suggest that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly, the P1 \u2018Brazilian\u2019 strain may be less resistant to these antibodies than first feared.
\n \n\n\n \n 5 March 2021\n \n
\n\n \n \n \n\n \n \n \nProfessor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce\u2019 (RSA) Albert Medal for her work on the Oxford vaccine. The lead researcher on the Oxford vaccine team, Professor Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.
\n \n\n\n \n 1 March 2021\n \n
\n\n \n \n \n\n \n \n \nToday Public Health England (PHE) has submitted a pre-print of a real-world study that shows that the Oxford / AstraZeneca and Pfizer vaccines are both highly effective in reducing COVID-19 infections among older people aged 70 years and over. Both vaccines had about 60% protection against symptomatic infection in this age group.
\n \n\n\n \n 22 February 2021\n \n
\n\n \n \n \n\n \n \n \nThe first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
\n \n\n\n \n 12 February 2021\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
\n \n\n\n \n 10 February 2021\n \n
\n\n \n \n \n\n \n \n \nWHO SAGE says Oxford's vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group. The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) yesterday produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca.
\n \n\n\n \n 5 February 2021\n \n
\n\n \n \n \n\n \n \n \nAnalyses reveal single standard dose efficacy from day 22 to day 90 post vaccination of 76% with protection not falling in this three-month period. After the second dose vaccine efficacy from two standard doses is 82.4% with the 3-month interval being used in the UK (82.4% effective, with a 95% confidence interval of 62.7% - 91.7% at 12+ weeks). Data supports the 4-12 week prime-boost dosing interval recommended by many global regulators. Analyses of PCR positive swabs in UK population suggests vaccine may have substantial effect on transmission of the virus with 67% reduction in positive swabs among those vaccinated.
\n \n\n\n \n 4 February 2021\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
\n \n\n\n \n 2 February 2021\n \n
\n\n \n \n \n\n \n \n \nResearchers at the University of Oxford have today published in Preprints with The Lancet an analysis of further data from the ongoing trials of the vaccine. In this, they reveal that the vaccine efficacy is higher at longer prime-boost intervals, and that a single dose of the vaccine is 76% effective from 22- to up to 90-days post vaccination.
\n \n\n\n \n 26 January 2021\n \n
\n\n \n \n \n\n \n \n \nToday, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
\n \n\n\n \n 4 January 2021\n \n
\n\n \n \n \n\n \n \n \nAt 7.30 am today, dialysis patient Brian Pinker became the very first person to be vaccinated as part of the UK\u2019s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, with patients at the Oxford University NHS Hospitals Trust becoming the first to receive this life-saving vaccine.
\n \n\n\n \n 30 December 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
\n \n\n\n \n 17 December 2020\n \n
\n\n \n \n \n\n \n \n \nToday, researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions.
\n \n\n\n \n 8 December 2020\n \n
\n\n \n \n \n\n \n \n \nToday University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
\n \n\n\n \n 23 November 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n